Discovery and clinical translation of novel glaucoma biomarkers

Prog Retin Eye Res. 2021 Jan:80:100875. doi: 10.1016/j.preteyeres.2020.100875. Epub 2020 Jul 10.

Abstract

Glaucoma and other optic neuropathies are characterized by progressive dysfunction and loss of retinal ganglion cells and their axons. Given the high prevalence of glaucoma-related blindness and the availability of treatment options, improving the diagnosis and precise monitoring of progression in these conditions is paramount. Here we review recent progress in the development of novel biomarkers for glaucoma in the context of disease pathophysiology and we propose future steps for the field, including integration of exploratory biomarker outcomes into prospective therapeutic trials. We anticipate that, when validated, some of the novel glaucoma biomarkers discussed here will prove useful for clinical diagnosis and prediction of progression, as well as monitoring of clinical responses to standard and investigational therapies.

Keywords: Axonal degeneration; Glaucoma; Nerve fiber layer; Retinal ganglion cell; Retinal imaging.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Axons / pathology
  • Biomarkers / metabolism*
  • Disease Models, Animal
  • Glaucoma / metabolism*
  • Glaucoma / physiopathology
  • Humans
  • Optic Nerve Diseases / metabolism*
  • Optic Nerve Diseases / physiopathology
  • Retinal Ganglion Cells / pathology

Substances

  • Biomarkers